

RECEIVED

JUN 23 2000

TC 1300 MAIL ROOM

David J. Pinskey et al.  
U.S. Serial No.:09/053,871  
Filed: April 1, 1998  
Page 2

REMARKS

Applicants have amended the specification to reflect the correct sequence number identifiers based upon the new sequence listing which is submitted herewith. Applicants have also included SEQ ID NOS:20-21 which are the nucleotide and amino acid sequences of wild-type Factor IX as requested by the Examiner.

Sequence Listing

The Examiner stated that this application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR §1.821 (a) (1) and (a) (2). The Examiner stated the application fails to comply with the requirements of 37 CFR §1.821 through §1.825 for the reason set forth on the attached Notice To Comply With Requirements For Patent Application Containing Nucleotide And/Or Amino Acid Sequence Disclosures (**Exhibit A**). The Examiner stated that applicants are required to identify all such nucleotide and amino acid sequences in the specification with SEQ.ID NOS., including those sequences disclosed on pages 20 and 21 of the instant specification.

In addition, the Examiner stated that in view of the newly added claims, especially claims 33, 34 and 38, which recite changes in specific residues of Factor IXa, as amended, applicant is required to provide a sequence listing for wild type Factor IX, in order to properly search the newly added claims.

In reply, applicants submit herewith a new Sequence Listing attached hereto as **Exhibit B** in compliance with the requirements of 37 C.F.R. §1.824. In addition, applicants submit herewith a computer readable copy of the Sequence Listing on the enclosed computer diskette, which has the same content as the paper copy attached as **Exhibit B**. Applicants submit as **Exhibit C**, a

David J. Pinskey et al.  
U.S. Serial No.:09/053,871  
Filed: April 1, 1998  
Page 3

Statement in accordance with 37 C.F.R. §1.821(f) certifying that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information which is submitted herewith as **Exhibit B** entitled "Sequence Listing". In addition, applicants have amended the specification to include references to SEQ ID NOS.

Furthermore, applicants have included the nucleic acid sequence and the amino acid sequence of wild-type Factor IX (see SEQ ID NOS:20-21) as requested by the Examiner in the sequence listing attached hereto as **Exhibit B**.

Thus, applicants maintain that the application now complies with the requirements of 37 C.F.R. §1.824 and request that the Examiner withdraw this objection.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

David J. Pinskey et al.  
U.S. Serial No.:09/053,871  
Filed: April 1, 1998  
Page 4



No fee, is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

*Jane M. Love*

I hereby certify that this correspondence  
is being deposited this date with the U.S.  
Postal Service with sufficient postage as  
first class mail in an envelope addressed  
to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

*Jane M. Love* 6/16/00  
John P. White Date  
Reg. No. 28,678  
Jane M. Love  
Reg. No. 42,812

John P. White  
Registration No. 28,678  
Jane M. Love  
Registration No. 42,812  
Attorneys for Applicants  
COOPER & DUNHAM LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400